Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)
(1)
,
(1)
,
(2)
,
(3)
,
(4)
,
(5)
,
(1)
,
(6)
,
(7)
,
(8)
,
(9)
,
(10)
,
(11)
,
(12)
,
(13)
,
(1)
1
2
3
4
5
6
7
8
9
10
11
12
13
2
3
4
5
6
7
8
9
10
11
12
13
Résumé
No abstract available